In contrast, decreased testosterone concentration in individuals with hypogonadism leads to obesity, decreased insulin sensitivity, and dyslipidemia, which is corrected by testosterone administration (Kelly and Jones, 2013; Sebo and Rodeheffer, 2021). The gene discussed is INS; the disease is hypogonadism.